News and Events | Spark Biomedical

January 22, 2020

Awards

Spark Biomedical Presents and Exhibits at the North American Neuromodulation Society 23rd Annual Conference

This is some text inside of a div block.

We invite you to join Spark Biomedical, Inc. as we present and exhibit at the North American Neuromodulation Society 23rd Annual Conference, Las Vegas, NV at Caesar’s Palace.

November 21, 2019

Clinical Trials

Spark Biomedical Launches Clinical Trial to Treat Opioid Withdrawal

This is some text inside of a div block.

Spark Biomedical, Inc., a neurostimulation device company developing solutions for opioid withdrawal, today announced open patient enrollment in their clinical trial to validate the company’s auricular neurostimulation device for opioid withdrawal relief — currently named “Phoenix.” Spark is partnering with CARMAhealth a collaborative primary care and psychiatric outpatient practice with a specialty focus on addiction medicine and Recovery Unplugged. Patients with opioid use disorder (OUD) will enroll in the trial at two Recovery Unplugged locations in Austin, Texas, and Lake Worth, Florida.

October 18, 2019

Press Releases

Spark Biomedical Receives $217K NIH Grant to Help Opioid-Addicted Newborns

This is some text inside of a div block.

FUNDS TO VALIDATE TRANSCUTANEOUS AURICULAR NEUROSTIMULATION FOR RELIEVING WITHDRAWAL SYMPTOMS IN INFANTS BORN WITH NEONATAL ABSTINENCE SYNDROME (NAS) Dallas, TX, October 18, 2019 — Spark Biomedical, Inc., a neurostimulation device company developing solutions for opioid withdrawal, received a $217,690 SBIR grant from the National Institutes of Health HEAL initiative. The grant (1R43DA050360-01) will be used to validate the use of neurostimulation to relieve withdrawal symptoms in infants born with neonatal abstinence syndrome (NAS).

May 20, 2019

Press Releases

Texas A&M alumnus’ biomedical company wins 2019 Texas A&M New Ventures Competition

This is some text inside of a div block.

A Texas A&M University former student’s startup, Spark Biomedical, was awarded $50,000 as the winner of the 2019 Texas A&M New Ventures Competition (TNVC) hosted by the Texas A&M Engineering Experiment Station (TEES). Daniel Powell is CEO of the medical device company, which is developing noninvasive neurostimulation solutions for opioid withdrawal and addiction.

May 6, 2019

Press Releases

Houston Based Galen Data and Spark Biomedical Reach Agreement

This is some text inside of a div block.

Partnership between Galen Data and Spark Biomedical strengthens their combined capability in support of connected medical devices and the ability to treat opioid withdrawal.

May 3, 2019

Awards

Spark Biomedical, Inc Semi-Finalist in Texas A&M New Ventures Competition

This is some text inside of a div block.

College Station, TX, May 3, 2019 — As Texas A&M New Ventures Competition 2019 #TNVC2019 approaches, May 15 – 17, the semi-finalist list has been announced. Spark Biomedical, Inc. is proud to be listed among the esteemed semi-finalists. Aimed at promoting the commercialization of emerging technology, the competition recognizes companies with high-growth potential and provides seed funding to help them effectively execute their ideas and advance product development.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

News & Events

News

Spark Biomedical Presents and Exhibits at the North American Neuromodulation Society 23rd Annual Conference

Spark Biomedical Launches Clinical Trial to Treat Opioid Withdrawal

Spark Biomedical Receives $217K NIH Grant to Help Opioid-Addicted Newborns

Texas A&M alumnus’ biomedical company wins 2019 Texas A&M New Ventures Competition

Houston Based Galen Data and Spark Biomedical Reach Agreement

Spark Biomedical, Inc Semi-Finalist in Texas A&M New Ventures Competition

Media Inquiries